Akero Therapeutics, Inc.

AKRO

Find Out if You Qualify for a Financial Reward by filling out the form below.

Lead Plaintiff Deadline:
June 25, 2024

Days Left:
-112

calendar

Akero Therapeutics, Inc. Form












Class Action Lawsuit List does not share your information with others. There is no cost or obligation for you to submit.

Allegations

The filed complaint alleges that defendants made false statements and/or concealed that: (i) approximately 20% of the patients enrolled in the SYMMETRY study, a trial that purportedly tested efruxifermin ("EFX") in patients with nonalcoholic steatohepatitis (“NASH”) -induced cirrhosis, had cryptogenic cirrhosis and did not have definitive NASH at baseline; (ii) the cryptogenic cirrhotic patients included in the SYMMETRY study did not have biopsy-proven compensated cirrhosis due to definitive NASH; (iii) the results from the cryptogenic cirrhosis patients were to be excluded from the calculation of the NASH resolution secondary endpoints; (iv) Akero had introduced a confounding factor into the SYMMETRY study’s design, materially influencing the study’s potential results and increasing the risks that the study would fail to meet its primary endpoint; (v) the SYMMETRY study did not align with U.S. Food & Drug Administration guidance for testing a drug in treating NASH cirrhotics because Akero had not rule out potential causes of each patient’s cirrhosis other than NASH; and (vi) consequently, Akero had materially misrepresented the nature of the SYMMETRY trial, its usefulness in supporting any new drug application, the likelihood that the SYMMETRY trial would be successful as measured by its primary endpoint, and the likelihood that EFX would become a commercial treatment for NASH cirrhotics.

Eligibility

In order to be included in the lawsuit, you must have incurred a loss on shares of Akero Therapeutics purchased or acquired during the class period listed above.

Lead Plaintiff Deadline

If you suffered a loss in Akero Therapeutics during the relevant time frame, you have until June 25, 2024 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Active Cases

Ticker Symbol Company Name Join Deadline Join
CXM Sprinklr, Inc. October 15, 2024 Join
STLA Stellantis N.V. October 15, 2024 Join
SYM Symbotic Inc. October 15, 2024 Join
EXTR Extreme Networks, Inc. October 15, 2024 Join
PDD PDD Holdings Inc. f/k/a Pinduoduo Inc. October 15, 2024 Join
ARDX Ardelyx, Inc. October 15, 2024 Join
OFIX Orthofix Medical Inc. October 21, 2024 Join
DXCM DexCom, Inc. October 21, 2024 Join
SPIR Spire Global, Inc. October 21, 2024 Join
STM STMicroelectronics N.V. October 22, 2024 Join
DAVA Endava plc October 25, 2024 Join
MEI Methode Electronics, Inc. October 25, 2024 Join
SAGE Sage Therapeutics, Inc. October 28, 2024 Join
VERV Verve Therapeutics, Inc. October 28, 2024 Join
SBUX Starbucks Corporation October 28, 2024 Join
OM Outset Medical, Inc. October 28, 2024 Join
SMCI Super Micro Computer, Inc. October 29, 2024 Join
ZI ZoomInfo Technologies Inc. November 04, 2024 Join
WBTN WEBTOON Entertainment Inc. November 04, 2024 Join
GTLB GitLab Inc. November 04, 2024 Join
GTLB GitLab Inc. November 04, 2024 Join
AGEN Agenus Inc. November 05, 2024 Join
NFE New Fortress Energy Inc. November 18, 2024 Join
MGX Metagenomi, Inc. November 25, 2024 Join
BMBL Bumble Inc. November 25, 2024 Join
UPS United Parcel Service, Inc. December 09, 2024 Join
EW Edwards Lifesciences Corporation December 13, 2024 Join